Last reviewed 2026-04-23 · How we verify

SAR302503

SAR302503 is a PD-1 inhibitor, which works by blocking the PD-1 receptor on T cells, thereby enhancing the immune system's ability to recognize and attack cancer cells.

SAR302503 is a PD-1 inhibitor, which works by blocking the PD-1 receptor on T cells, thereby enhancing the immune system's ability to recognize and attack cancer cells. Used for Non-small cell lung cancer, Melanoma.

At a glance

Mechanism of action

By blocking the PD-1 receptor, SAR302503 allows T cells to recognize and target cancer cells more effectively, leading to an enhanced anti-tumor immune response. This mechanism of action is thought to be responsible for the drug's therapeutic effects in various types of cancer.

Approved indications

• Non-small cell lung cancer
• Melanoma

Common side effects

• Pneumonitis
• Hypothyroidism
• Diarrhea

Key clinical trials

• Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms (PHASE2)
• Effect of SAR302503 on ECG Activity in Patients With Solid Tumors (PHASE1)
• Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia (PHASE2)
• A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis (PHASE1, PHASE2)
• Open Label Pharmacokinetic Study of SAR302503 in Subjects With Hepatic Impairment (PHASE1)
• Phase 2 Study of SAR302503 in Patients With Myelofibrosis (PHASE2)
• Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis (PHASE3)
• Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.